| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.5 |
| mRNA | KIN001-135 | GDSC1000 | pan-cancer | AAC | 0.033 | 0.5 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | BRD9876 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | 0.019 | 0.5 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.5 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.5 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |